SLO-NIACIN^® Tablets—take an active role in raising your HDL

Keeping your blood lipid levels within a healthy range is an important step in maintaining overall heart health. In addition to total cholesterol and LDL cholesterol, HDL cholesterol (or "good" cholesterol) is an important independent risk factor for cardiovascular disease.

Studies show that increased levels of HDL cholesterol help reduce your risk of heart disease. In fact, a 1 mg/dL increase in HDL is associated with a 2% to 3% decrease in coronary risk.¹ So, even a small improvement in HDL levels contributes to decreasing your risk.

Recommendations for heart health

The following guidelines from the National Cholesterol Education Program (NCEP) outline recommended blood lipid levels.²

LDL cholesterol (mg/dL)
<100	Optimal
100-129	Near optimal
130-159	Borderline high
160-189	High
≥190	Very high
Total cholesterol (mg/dL)
<200	Desirable
200-239	Borderline high
≥240	High
HDL cholesterol (mg/dL)
<40	Low
≥60	High
Triglycerides (mg/dL)
<150	Normal
150-199	Borderline high
200-499	High
≥500	Very high

 

SLO-NIACIN^® Tablets are clinically proven to raise HDL levels^3,4—SLO-NIACIN^® Tablets as monotherapy (used alone) and in combination with another cholesterol medication (simvastatin)

• Raised HDL "good"cholesterol—between 18% and 26%
• Lowered LDL "bad" cholesterol—between -13% and -42%
• Lowered total cholesterol—by 9%³
• Lowered triglycerides—between -20% and -36%

 

SLO-NIACIN^® Tablets + simvastatin lipid changes from baseline⁴

Average daily dose: niacin* 2400 mg ± 2000 mg; simvastatin 13.6 mg ± 6 mg. N=33.

Study design:
The HATS trial (HDL-Atherosclerosis Treatment Study) enrolled 160 men (younger than 63 years of age) and women (younger than 70 years of age) with clinical coronary disease (defined as previous myocardial infarction, coronary interventions, or confirmed angina) and with at least three stenoses of at least 30% of the luminal diameter or one stenosis of at least 50%. Twenty-six patients in Canada and 134 patients in the Seattle area were enrolled between January 1995 and January 1997. All patients had low levels of HDL cholesterol (<35 mg/dL for men and <40 mg/dL for women), LDL cholesterol levels of 145 mg/dL or less, and triglyceride levels of 400 mg/dL or less.

*All niacin (both SLO-NIACIN^® Tablets and NIACOR^®) supplied and manufactured by
  Upsher-Smith Laboratories, Inc.

 

SLO-NIACIN^® Tablets also

• Halted the progression of stenosis (closing of the arteries)⁴
• Reduced the risk of a cardiovascular event, such as a heart attack, by 90% compared to placebo⁴

 

References:

1. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation.1989;79:8-15.
2. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
3. Squires RW, Allison TG, Gau GT, Miller TD, Kottke BA. Low-dose, time-release nicotinic acid: effects in selected patients with low concentrations of high-density lipoprotein cholesterol. Mayo Clin Proc. 1992;67:855-860.
4. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345(22):1583-1592.